The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
AY-9944 ID: ALA2062162
Max Phase: Preclinical
Molecular Formula: C22H28Cl2N2
Molecular Weight: 391.39
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Synonyms: AY-9944
Canonical SMILES: Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1
Standard InChI: InChI=1S/C22H28Cl2N2/c23-21-7-3-1-5-19(21)15-25-13-17-9-11-18(12-10-17)14-26-16-20-6-2-4-8-22(20)24/h1-8,17-18,25-26H,9-16H2/t17-,18-
Standard InChI Key: RZRPZWGIOOZIBE-IYARVYRRSA-N
Molfile:
RDKit 2D
26 28 0 0 0 0 0 0 0 0999 V2000
1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6003 -1.4978 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8990 -0.7455 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-5.2003 -1.4932 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.4990 -0.7410 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.8007 -1.4864 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.0971 -0.7319 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.0919 0.7681 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.7903 1.5136 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.4939 0.7591 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.3907 1.5203 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-11.6919 0.7725 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-12.9906 1.5248 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-14.2919 0.7770 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-15.5910 1.5269 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-16.8901 0.7769 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-16.8900 -0.7231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-15.5910 -1.4731 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-14.2920 -0.7231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -2.7000 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-15.5911 2.7269 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
5 7 1 0
7 8 1 0
8 9 1 0
10 9 1 1
10 11 1 0
10 15 1 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
13 16 1 6
16 17 1 0
17 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 19 1 0
6 25 1 0
20 26 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 391.39Molecular Weight (Monoisotopic): 390.1630AlogP: 5.68#Rotatable Bonds: 8Polar Surface Area: 24.06Molecular Species: BASEHBA: 2HBD: 2#RO5 Violations: 1HBA (Lipinski): 2HBD (Lipinski): 2#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 9.38CX LogP: 5.83CX LogD: 2.48Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.61Np Likeness Score: -0.69
References 1. Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.. (2007) Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential., 47 (1): [PMID:17428028 ] [10.1021/ci6004542 ] 2. Lowe R, Glen RC, Mitchell JB.. (2010) Predicting phospholipidosis using machine learning., 7 (5): [PMID:20799726 ] [10.1021/mp100103e ] 3. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.. (2008) Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models., 18 (2): [PMID:20020916 ] [10.1080/15376510701857262 ] 4. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361 ] 5. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148 ]